Revelation Biosciences Free Cash Flow (FCF) History (REVB)
Revelation Biosciences reported −$18.3M in free cash flow for fiscal 2024, a decrease of $7.1M from the previous fiscal year.
View full Revelation Biosciences company overviewRevelation Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$18.3M | −$7.1M | — | — |
| 2021 | 2021-12-31 | −$11.2M | — | — | — |
Revelation Biosciences quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.6M | −$118,139 | — | — |
| Q1 2026 | 2026-03-31 | −$3.3M | −$429,589 | — | — |
| Q4 2024 | 2024-12-31 | −$3.8M | −$2.0M | — | — |
| Q3 2024 | 2024-09-30 | −$9.3M | −$7.3M | — | — |
| Q2 2024 | 2024-06-30 | −$2.5M | −$903,528 | — | — |
| Q1 2024 | 2024-03-31 | −$2.9M | $37,919 | — | — |
| Q3 2023 | 2023-09-30 | −$1.7M | $517,979 | — | — |
| Q2 2023 | 2023-06-30 | −$2.0M | $1.7M | — | — |
| Q1 2023 | 2023-03-31 | −$1.6M | $905,999 | — | — |
| Q4 2021 | 2021-12-31 | −$2.9M | — | — | — |
| Q3 2021 | 2021-09-30 | −$2.2M | — | — | — |
| Q2 2021 | 2021-06-30 | −$3.6M | — | — | — |
| Q1 2021 | 2021-03-31 | −$2.5M | — | — | — |
Revelation Biosciences free cash flow growth trends
Revelation Biosciences's latest reported quarter, Q2 2026, generated −$2.6M in free cash flow, a decrease of $118,139 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Revelation Biosciences filings at SEC.gov ↗